Why the study?
Although GERD is highly prevalent in patients with CVD, its role in cardiovascular disease remains unclear despite studies implicating GERD and its therapies as CVD risk factors.
Does gastroesophageal reflux disease (GERD) and its medical, lifestyle, or surgical management impact the incidence, progression, and mortality of cardiovascular disease?
Does gastroesophageal reflux disease (GERD) and its medical, lifestyle, or surgical management impact the incidence, progression, and mortality of cardiovascular disease?
Answers are grounded in this paper and cite their sources.
This narrative review highlights growing observational and genetic evidence implicating gastroesophageal reflux disease (GERD) and long-term proton pump inhibitor therapy as potential risk factors for cardiovascular disease through shared risk factors, endothelial dysfunction, and autonomic imbalance.
Gastroesophageal reflux disease (GERD) is a very common disease with an estimated 442 million cases worldwide. It is a well-documented independent risk factor for many gastrointestinal pathologies, however, its role in cardiovascular disease (CVD) is unclear, despite its high prevalence in patients with CVD. Although traditionally considered a causative agent of noncardiac chest pain, a common imitator of cardiac chest pain, or an incidentally shared comorbidity in patients with CVD, a number of studies have implicated GERD and its therapies as risk factors for CVD. This narrative review will explore the relationship between GERD and CVD, including medical and mechanical therapeutic approaches for GERD that could potentially impact the incidence, progression, and mortality of CVD.
No takes yet. Share an insight, caveat, or question.
Gries et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: